Product Description
Amiselimod is a sphingosine-1-phosphate (S1P) receptor functional antagonist and, by inhibiting the receptor function of the lymphocyte sphingosine-1-phosphate (S1P) receptor, retains lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions.1 Due to this mechanism of action, Amiselimod may potentially be useful for various autoimmune diseases.2 Affinity to S1P1 and S1P5 receptor subtypes, suggests that Amiselimod could potentially have a more pronounced effect on ulcerative colitis related inflammation than compounds with restricted activity on S1P1 receptor subtype exclusively or combined activity on S1P1 and S1P5. (Sourced from: https://ir.bauschhealth.com/news-releases/2024/05-17-2024)
Mechanisms of Action: S1P1 Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Mitsubishi Tanabe
Company Location: Asia Pacific
Company Founding Year: 2007
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belarus, Bulgaria, Czech Republic, Georgia, Germany, Hungary, Italy, Moldova, Poland, Russia, Serbia, Taiwan, Ukraine, United States, Unknown Location
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Bausch Health Americas presented P2 Colitis, Ulcerative results on 2024-05-19 for Amiselimod
Highest Development Phases
Phase 2: Colitis, Ulcerative
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04857112 |
AMUC-2023 | P2 |
Completed |
Colitis, Ulcerative |
2024-09-03 |
2025-08-30 |
Primary Endpoints|Treatments |
|
2020-005232-30 |
2020-005232-30 | P2 |
Completed |
Colitis, Ulcerative |
2024-09-03 |
2025-07-06 |
Treatments |
|
jRCT2031210352 |
jRCT2031210352 | P2 |
Active, not recruiting |
Colitis, Ulcerative |
2023-10-31 |